You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: January 18, 2021

DrugPatentWatch Database Preview


➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Risperidone patents expire, and what generic alternatives are available?

Risperidone is a drug marketed by Amneal Pharms, Ani Pharms Inc, Aurobindo Pharma Ltd, Hikma, Lannett Co Inc, Pharm Assoc, Precision Dose, Taro, Torrent, Tris Pharma Inc, Wockhardt, Actavis Labs Fl Inc, Dr Reddys Labs Ltd, Heritage Pharma, Jubilant Generics, Mylan Pharms Inc, Par Pharm, Sandoz, Sun Pharm Inds Ltd, Zydus Pharms Usa, Ajanta Pharma Ltd, Amneal, Apotex Inc, Celltrion, Chartwell Molecular, Jubilant Cadista, Mylan, Prinston Inc, Ratiopharm, Renata, Rising, Sun Pharm Inds Inc, Synthon Pharms, Torrent Pharms, Watson Labs, West Ward Pharms, and Zydus Pharms Usa Inc. and is included in forty-four NDAs.

The generic ingredient in RISPERIDONE is risperidone. There are thirty drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the risperidone profile page.

US ANDA Litigation and Generic Entry Outlook for Risperidone

A generic version of RISPERIDONE was approved as risperidone by APOTEX INC on September 15th, 2008.

  Start Trial

Drug patent expirations by year for RISPERIDONE
Drug Prices for RISPERIDONE

See drug prices for RISPERIDONE

Drug Sales Revenue Trends for RISPERIDONE

See drug sales revenues for RISPERIDONE

Recent Clinical Trials for RISPERIDONE

Identify potential brand extensions & 505(b)(2) entrants

University of GeorgiaPhase 4
Hartford HospitalPhase 4
University of Texas Southwestern Medical CenterPhase 4

See all RISPERIDONE clinical trials

Pharmacology for RISPERIDONE
Medical Subject Heading (MeSH) Categories for RISPERIDONE
Paragraph IV (Patent) Challenges for RISPERIDONE
Tradename Dosage Ingredient NDA Submissiondate
RISPERDAL TABLET;ORAL risperidone 020272
RISPERDAL SOLUTION;ORAL risperidone 020588

US Patents and Regulatory Information for RISPERIDONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Inc RISPERIDONE risperidone TABLET;ORAL 077953-001 Sep 15, 2008 AB RX No No   Start Trial   Start Trial   Start Trial
Heritage Pharma RISPERIDONE risperidone TABLET;ORAL 077769-003 Oct 16, 2008 DISCN No No   Start Trial   Start Trial   Start Trial
Par Pharm RISPERIDONE risperidone TABLET, ORALLY DISINTEGRATING;ORAL 077494-005 Apr 30, 2009 AB RX No No   Start Trial   Start Trial   Start Trial
Mylan Pharms Inc RISPERIDONE risperidone TABLET, ORALLY DISINTEGRATING;ORAL 091537-001 Mar 30, 2011 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.